Results obtained in a phase I clinical study of the new drug were presented in Berlin, on November 19th, at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. ACE-041 aims at the receptor known as ALK-1 (activin receptor-like kinase-1), which is responsible for regulating the formation of new networks containing blood vessels that are needed for the growth of tumours. This process is known as angiogenesis. Existing anti-angiogenic drugs, including sunitinib, bevacizumab and sorafenib are targeting other angiogenesis receptors like VEGF, while ACE-041 is among the first drugs to target the ALK-1.

Professor Sunil Sharma, who is the Jon and Karen Huntsman Presidential Professor of Cancer Research at the Huntsman Cancer Institute of the Utah University in Salt Lake City, USA, said that the connection between angiogenesis and ALK-1 was made by discovering that mutations in the ALK-1 gene had caused a condition named HHT2 (hereditary haemorrhagic telangiectasia 2, characterised by diminished formation of capillary beds, which causes red markings at the level of the skin.

A technology company in Cambridge, Massachusetts, USA, Acceleron Pharma, has designed ACE-041 aiming to inhibit ALK-1 signalling and has asked Professor Sharma to be one of the investigators who would conduct the first-in-man phase I clinical test of the drug in order to see if it really would halt tumour angiogenesis.

Professor Sharma said that since ALK-1 was transiently expressed on proliferating cells lining the inner surface of the blood vessels (endothelial cells), while VEGF receptors were constitutively expressed on endothelial cells and other types too, it would be a more selective target when trying to inhibit angiogenesis. ALK-1 expression on the vasculature of the tumour has been noticed on biopsy samples of a wide range of tumours.

The phase I of the study comprised patients with a diversified range of advanced solid tumours that already spread to other parts of the body or simply were inoperable like multiple myeloma, neck and head cancers, NSCLC (non-small cell lung cancer) and carcinoid tumours (carcinoma type neuroendocrine tumours usually originating in the appendix or small intestine). Many of the patients had been unsuccessfully treated with a series of other treatments, which included anti-VEGF drugs, before this trial. ACE-041 has been administrated via subcutaneous injections.

Professor Sharma said that, early in September, 25 patients have been included in the study and ACE-041 dose level has been escalated from 0.1 mg/kg to 4.8 mg/kg. In the case of a patient with neck and head cancer, the response was partial, while three patients have shown positive responses as determined by FDG-PET scans. ACE-041 has been well tolerated by the patients, with some adverse events like peripheral oedema, anaemia, headache, nausea and fatigue.

Seeing many signs of efficacy during the trial has been quite encouraging for the medical team, particularly because of the structure of the study population. They were patients with end-stage cancer, already treated with and refractory to multiple standard therapies. It has equally been encouraging to note signals of activity of ACE-041 in a wide series of tumour types, thus confirming the hypothesis that ACE-041 may really act against tumours with agiogenic activity, no matter what histology they had. Another important aspect to be noted was the demonstration of the significant activity with ACE-041 monotherapy during the study, which leads to expectations of more efficacy in future studies including ACE-041 combined with other therapies.

Professor Sharma and his team planned further investigations related to the safety and tolerability of ACE-041 in an additional group of cancer patients and look forward to start a phase II study in 2011.

According to Professor Sharma, the anti-VEGF angiogene inhibitors, which include sunitinib, bevacizumab and sorafenib, have represented an important contribution to the armamentarium of therapies against cancer. However, the efficacy is in a way limited because tumours could eventually develop an ability to simulate angiogenesis using non-VEGF angiogenic factors. Serious side-effects appear from effects on blood vessels found in normal tissues. ACE-041 inhibits angiogenesis in a totally different way and therefore it might have synergistic efficacy with VEGF-based inhibitors. It may be effective for patients who have manifested resistance to VEGF inhibitors.

The investigation was released in the Cancer Research journal in its October edition. The investigators from the University of Texas Southwestern Medical Center discovered that if they gave the mice the BEZ235 medication prior to undergoing harmless radiation in order to counteract the cancerous cell development of DNA, the BEZ235 would counteract the activity of the PI3K protein which typically acts as a guardian of the tumor cells. This protein maintains the cancerous cells in life in the moment they are attacked and try to heal their broken DNA.

Besides the leading author, the team of investigators from the University of Texas comprised: doctor Erik Bey from the Harold C. Simmons Comprehensive Cancer Center, doctor Andrea Rabellino, doctor Katja Schuster, doctor Adi Gazdar, professor within the University of Texas Southwestern, Jake Hamon from the Center for Therapeutic Oncology Research, doctor David Boothman from the Simmons Comprehensive Cancer, researchers coming from the University of Camerino in Italy and Novartis Pharma in Switzerland. Their investigation was financed by funds coming from National Institutes of Health, American Cancer Society, Concern Foundation, Gibson Foundation, Leukemia of Texas, United States Department of Energy and the American Italian Cancer Foundation.

The scientists observed this treatment opportunity in mice that underwent a transplant process with non-small cell lung cancer tumors from human beings.

During their observation process, the researchers discovered that the malignant tumors developing in the mice which were treated with just the BEZ235 has a decrease in size compared to those affecting mice which were not undergoing any type of treatments. Even though the malignant tumors did not grow in size, their life was not ended by administering the specific medication.

On the other hand, mice undergoing the BEZ235 treatment combined with low-dose radiation recorded many cases of total elimination of the malignant tumors.

The leading investigator was doctor Pier Paolo Scaglioni who is assistant professor of the internal medicine department within the University of Texas Southwestern. He stated that the findings of his research team regarding the combination of medication and low-dose radiation may prove to become an efficient treatment for counteracting non-small cell lung cancer in human beings.

The non-small cell lung cancer represents one of the main causes of cancer connected mortality on the whole Globe. The malignant cells usually favor transformations in the K-RAS which is a gene. People suffering from mutations of the K-RAS usually present an increased resistance to therapies comprising irradiation. This is the cause for which their life perspectives are unfavorable.

The K-RAS transformations trigger the networks or different pathways of various proteins that act as signals to activate. This signaling represents a key element in the development and growth of a malignant tumor. The PI3K represents just one of these proteins. At the moment of activation, it acts as a guardian which aids the cells in maintaining living functions even after their DNA was damaged and they try to heal it.

Some of the elements forming the signal networks comprising also the PI3K protein have been explored as various medication targets for counteracting malignant tumors. The clinical tested medication BEZ235 has been recently in experiments comprising clinical tests for counteracting the activity of the PI3K and the mTOR which represents a signaling protein, also.

As the leading investigator states there is no efficient treatment counteracting the non-small cell lung cancer which hosts transformations of the K-RAS.

Medical doctor Pier Paolo Scaglioni conducted the first tests in order to identify the efficacy of the BEZ235 drug and thus, they tested it alone. The team of investigators discovered that the BEZ235 stops the evolution and growth of the lung cancer malignant cells that were developed in the laboratory and the malignant lung cells that affect the mice.

As the leading author of this first research, doctor Georgia Konstantinidou states the findings of the investigators were shocking. However, they strived to discover a way for a faster malignant cell deterioration. They found put that by combining the tested medication with low-dose radiation, the success of their mission was assured. Doctor Georgia Konstantinidou is a post-doctoral scientist within the University of Texas Southwestern.

Doctor Pier Paolo Scaglioni`s research group observed that the malignant cells which were treated with the BEZ235 medication and low-dosed irradiation. The latter triggered slight breaks in the cellular genetic material but did not managed to affect them in a more effective way in order to destroy them. At the moment the DNA of the cell is broken, the malignant cells are aided by the PI3K signaling network in order to assure the cancer cell`s survival while it is healing its genetic material.

The team of investigators explained that the malignant cells needed the PI3K signaling pathway to assure they remain alive and without the protein`s response they were prone to die. This is why in the moment the scientists administered the BEZ235 medication it stopped the action of the PI3K protein and this means that the non-small cell lung cancer cells were starting to die.

As the leading author of the research explains the future stage of the study is that of administering the BEZ235 medication or similar drugs in clinical tests against the non-small cell lung suffering human beings. This could also be applied in clinical trials comprising people suffering from other types of malignant cells such as pancreatic, colon and thyroid cancers. There are the same with the non-small cell lung due to the fact that the PI3K signaling network also acts as an important agent in the malignant cells` evolution.

This environmental report is just a part of the process of taking care of the continuous and newly discovered problems regarding the pollutant agents of the environment and cancer. Moreover, the scope of the report is to shed more light on the principles, mission, values, objectives and various roles of the American Cancer Society on issues such as those mentioned before: pollution and malignant tumors prevention.

As the co-chair of the subcommittee and chairman of the Department of Preventive Medicine within the Keck School of Medicine of University of Southern California, medical doctor Jonathan Samet explains the problems regarding the environmental pollution agents affecting the air, water, food and thus, customer products represent issues on general public care and high unknowns. He also adds that their report aims to put the pollution agents of the environment in a greater relationship with preventing malignant tumors. The relationship focuses on reducing the smoking habit of the population, improving nutritional behavior, increasing the physical activities, maintaining a proper body weight and come up with vaccines that counteract the infections which may cause cancers.

The other co-chair of the subcommittee is also volunteer president of the American Cancer Society. Her name is Elizabeth “Terry” T.H. Fontham and she stated that the exposure levels of the population to chemical and pollution agents affecting the environment are much lower than the levels linked to the showed predisposition to developing malignant tumors in the jobs people have and other daily settings. However, the concern raised by the low exposure levels has to do with the fact that the number and types of pollution substances are increasing and may prove in the future to get out of the population`s control. In addition, the problems related to the fact that even low exposure levels bring some contribution to the cancer developing cases cause more reasons for distress considering the high number of persons who are daily exposed to the environmental pollutants.

The subcommittee`s report states that the scientific problems related to the exposure of people to the environmental pollutants represent complex issues just like increase in the number of landscape technologies which are utilized to analyze the chemical carcinogenicity. In spite of the capability of the nowadays tools used to identify and categorize proves for carcinogenicity, the subcommittee`s article states that there exist three main problems which constrain them from using them because there is a limited quantity of resources which are allotted to function those specific systems and from a scientific point of view, the environmental problems are complex and uncertain.

The report`s concerns about cancer vary and are related to malignant tumors prevention. There is a high need for new stratagems related to the tests done to evaluate the environment`s toxicity, comprising also the evaluation of carcinogenicity. These new strategies could be incorporated in such a manner as to assure a more efficient and effective screening process of a higher number of chemical agents which affect people daily. In addition, exposure to occupational and community settings should be regulated by some standards. The subcommittee draws attention on the need to support investigations aimed at identifying and decreasing the number of hazards provoked by carcinogens. Furthermore, the institutions that determine and implement standards for the environment must meet proper financing and appropriate technology in order to be near the scientific evolution and upgrade their set standards according to the new available data.

Even though some exposure cannot be avoided, this type of exposure must be somehow diminished and even stopped in the cases where it is possible to do so. In addition, the population must receive information about these matters in order to know their health status and risk of cancer or other diseases. Last, but not least, the media communication must make people aware of the situation of the exposure in an accurate manner and not to exaggerate or diminish the importance and level of environmental pollution factors.

The subcommittee’s report states that in order to create and implement this new initiative in order to assure the acquiring of more knowledge regarding the association between the levels of exposure to environmental pollution agents and the predisposition to various types of cancers, the American Cancer Society is going to further develop its long-run commitment to preventing malignant tumors. In addition, the American Cancer Society is also keen on studying these problems more thorough in order to discover new ways in which the initiative could bring more benefits in an effective and efficient manner.

Their discoveries are released in The Proceedings of the National Academy of Sciences. The recent study presents the way the cells of the naked mole rats generate a gene entitled p16 which triggers a claustrophobic characteristic. In turn this phobic state brings to a stop the multiplication of the cells in the case a big number of them becomes crowded. This means that the process impedes the abnormal growth even before it could commence. The effects of the p16 gene are so strong that at the time the scientists triggered mutations in the cell in order to develop a tumor, the growth of the cells did not transform very much. This is a very important discovery due to the fact that when applied on normal mice cells, the mutations would lead to malignant tumors creation.

Vera Gorbunova from the University of Rochester is the leading researcher of this investigation. The associate professor states that her team believes that they have discovered the reason for which the naked mole rats do not develop malignant tumors and it came as a shock to them. The implications of their discovery are many and important, but the speculations of stimulating the p16 gene in the case of human beings are just a matter of time and research. It this process could be accomplished in the case of people, this would represent the means to stop cancer evolution even before it can be triggered by various factors.

This species of rodents look rather strange; they have an unpleasant appearance because they have no hair covering their body and they live underground forming naked mole rats communities. In comparison to other mammals, the naked mole rats gatherings comprise queens and workers which is an odd feature due to the fact that this hierarchy is commonly found in bees. The rodents have a life span of approximately thirty years, a figure which is very big compared to the normal lifespan of tiny rats.

Even during the investigation a high number of naked mole rates were observed, the team of scientists did not manage to induce or find any animal presenting cancer tumors. A curiosity which also arises on these mammals` behalf is the fact that they grow older at a faster pace in the near end of their lives, whereas they age just a bit during their normal lifespan.

Vera Gorbunova, accompanied by a fellow researcher Andrei Seluanov who is a professor of biology within the University of Rochester, underwent an investigation which lasted for three years. During their research, the two scientists strived to study naked mole rats from all over the world in order to better understand the similarities of the species and what differentiated each group coming from different regions from one another. Moreover, the researchers wanted to acquire more information on how these differences and similarities were related to the naked mole rats ability to not develop cancer.

In the year 2006, Vera Gorbunova found out that an enzyme which can trigger a longer lifespan of the cells which is entitled telomerase has an enhanced activity in the case of small rats but not in larger ones. The telomerase enzyme is also a factor which can enhance malignant tumors` rate.

Prior to the investigation of Gorbunova and Seluanov, the existing idea was that any animal which had a lifetime span similar to the human beings` one had to stop or diminish the activity of the cells` telomerase in order to prevent malignant tumors from developing. This enzyme aids the cells in their reproducing stage and being well-known that cancer is the abnormal growth and multiplication of cells, any animal that could live for seventy years presented a high predisposition for developing cancer. The life span of a mouse is decreased due to natural agents like, for example, predators. This is why past wisdom stated that mice could manage a small risk for developing malignant tumors in order to enable the telomerase`s action and heal in at a faster pace.

Even though these beliefs were shattered by this new investigation, a new vagueness appeared. What is the case of animals that live for more than 24 years, like the well-known grey squirrel, for example? Considering the amplitude of the telomerase expression in these mammals due to a long time span, why do not they develop malignant tumors?

Vera Gorbunova strived to provide answers to these questions and in the year 2008 she discovered that the small rodents which enjoyed a longer lifetime span had evolved so much that their organism developed a method of counteracting cancer. This interesting mechanism differs a lot from other large animals and human beings` way to fight naturally against cancer.

At that specific moment, the assistant professor did not manage to discover which the cancer prevention mechanism in the naked mole rates was. As she explains past research was not able to identify this anti-malignant tumors mechanism due to the fact that scientists used only common mice and human beings` samples in their clinical and laboratory tests. The mouse is a mammal that has a short life span and people have large bodies. This is why the investigators found out that the anti-cancer mechanism is present only in the case of mammals that have a long life span and are very small.

By conducting this new investigation, Vera Gorbunova thinks she has discovered the first and main reason for which the naked mole rodents do not develop malignant tumors. It seems that this anti-cancer mechanism comprises a gene with a sort of early signal of attention that the mammal expresses in its body cells.

In the moment the team of researchers started to observe the cells coming from naked mole rats, they were shocked to discover just how hard it was for them to grow cells in the laboratory. The in vitro cells just stopped multiplying at the moment when they reached a specific number in a certain location. Human cells, for example, refused to replicate when they grew great in number, but in the case of the naked mole rodents this stopping of cell multiplication was triggered in an earlier stage compared to human beings and large mammals.

As the leading investigator explains cancer represents an abnormal multiplication of the body`s cells. But her team discovered that the process which triggered cancer development was also the factor which prevented the malignant tumors` formation in the naked mole rats.

Similar to human beings and a great number of animals, the naked mole rats comprise a gene entitled p27 which has the role to stop the dense growth of cells. However, the latter also utilize the p16 gene as an early warning signal. It has been shown that cells find ways to avoid the activity of the p27 gene, but the tiny hairless rodents enjoy double means of stalling and stopping the abnormal cellular growth.

As the leading author of the study states the team thinks that another protection layer produced by the action of these two genes (p16 and p27) triggers the ability of the naked mole rats to prevent malignant tumor appearance in their organism.

The two investigators plan to investigate more this issue and take a closer look at the genetic features of the naked hairless rodents in order to observe if their resistance to malignant tumors` development could be used in the case of human beings.

The investigation was released in the Alcoholism: Clinical and Experimental Research edition. The study comprises the researchers` findings regarding how alcohol triggers the epithelial-to-mesenchymal transition. During this transition, the mild cancerous cells transform in aggressive one and start invading the whole body in a process entitled metastasis.

As assistant professor Christopher Forsyth from the medicine and biochemistry division within the Rush University Medical Center explains the information provided by the team of investigators led by him is the first of its kind. This is due to the fact that their data presents the pathway in which alcohol stimulates specific triggers within a cell which are implicated in the metamorphosis into an aggressive form of the cells.

The notion of epithelial-to-mesenchymal transition is a highly researched matter nowadays due to the fact that it represents one of the processes involved in the mechanism of cancer spreading in the whole organism. An amalgam of laboratory investigations and clinical trials shows that this epithelial-to-mesenchymal transition is a prime factor in triggering the aggressiveness of the cancerous cells.

Professor Christopher Forsyth stated that the malign cells acquire a dangerous characteristic in the moment when they start spreading in the whole body. The operations can resection a malign tumor, but the aggressive cells have the ability to spread out in the whole human organism and conquer it. If medical doctors could stop this process, they would be able to limit the spreading of the malignant tumors.

The team of investigators put alcohol in cellular lines coming from colon and breast cancers and observed them in order to find the biochemical distinct signs of the epithelial-to-mesenchymal transition also including the presence of both Snail which is a transcription agent and the receptor concerned with the growth agent of the epidermis. The Snail represents the epithelial-to-mesenchymal transition`s control factor. On experiments undergone on mice, it was observed that if there is an over-expression of this factor, multi tumors are prone to develop. The second agent, the epidermal growth one is just like a drug for the cancer cells, they require large quantities of it.

The testing undergone in laboratories proves that alcohol triggered both factors and also other biochemicals agents related to the epithelial-to-mesenchymal transition. The trials also proved that the cells which were put in alcohol lost their strong links to adjacent cells, a characteristic which resembles the metastasizing process of the malign tumors.

Furthermore, professor Christopher Forsyth`s team of researchers discovered that the similar group of biomarkers was triggered in healthy intestinal cells which were put in alcohol. In addition to the aggressive metamorphosis alcohol triggers in cancer cells, this finding could mean that alcohol may also trigger the development of cancer.

This newly released screening framework is just the first step of the scientists from the M. D. Anderson Cancer Center to enhance the efficiency of forewarn and discover malignant tumors in their earliest development stage. Discovering cancer at this early development stage is of great importance because it can be more effectively treated through means such as rebuilding and developing even further its screening process. In addition, by doing this the risk of evolution and remission decreases and the worldwide medical world can acquire new diagnostic frameworks related to eight illness sites.

The suggestions regarding the screening process can be found on the Internet site of M. D. Anderson Cancer Center. These guidelines explain in a more comprehensible manner the best actions of admonishing malignant tumors that are undergone at this cancer center. This framework of practices is available for the general public to understand and it comprises the discovered risk classification and information regarding screening such as when it is most appropriate to start it and when it is all right to stop it.

As the American Cancer Society presents, over more than 40% of United States inhabitants are prone to suffer from malignant tumors during their life span. Furthermore, the types of cancer that can be avoided or discovered in early development stages due to screening sum up for minimum 50 percent of all these new malignant tumor occurrences.

Therese Bevers is the medical director of the M. D. Anderson’s Cancer Prevention Center. As the medical doctor state the screening process is not a generalized procedure. It depends on the individual. The center`s new suggestions aim to be more individualized, customized and more accurate. The new framework offers a more thorough recommendation compared to what was in the past made publicly available by other cancer institutions or by M. D. Anderson’s Cancer Prevention Center itself.

Until this recent investigation, suggestions for the screening process were dedicated in a larger manner to people who presented an average risk of suffering from cancer. These past recommendations based themselves on features such as age and family and genetic history and risk. Nonetheless, this average predisposition had not been clearly formulated and suggestions for people who presented a high risk of developing malignant tumors were not presented.

With the appearance of this new research there come new recommendations regarding cancer screening comprised in a new framework. These suggestions target individuals who present an increased predisposition of suffering from cancer. A feature which differentiates this new set of guidelines is, for example, the fact that the new framework comprises five various sets of suggestions for cancer screening for people who show a high predisposition of developing cancer, four categories of suggestions regarding cervical malignant tumors from the point of view of age-related risk. Regarding the colorectal malignant tumors, three new categories are presented in this new set of screening guidelines targeting people who present a high predisposition of developing this type of cancer and other three categories targeting individuals who show an increased predisposition for the colorectal cancer.

This new developed framework is constructed based on the early accepted screening activities, but it is more accurate and specific in offering suggestions, as follows:

Guidelines for Breast Cancer

Beginning with the age of 20 years, women who present all the predisposition levels of developing breast malignant tumors should take a closer look at the anatomy of their breasts and palpate them in order to discover whether sudden changes have appeared. If they notice a transformation of their breasts, the females should immediately go to their doctor and present their situation. Women who are 40 years or older and present an average predisposition to breast cancer should get breast tests and mammograms on a yearly basis.

For those females who present a high risk of developing malignant breast tumors, the frequency and variety of the breast tests depend on agents that represent their enhanced predisposition such as: their family history and thus, genetic risk, the past radiation therapy for counteracting breast tumors, a Gail Model score above 1.7% and the lobar carcinoma diagnosis established on the ground. Therapies recommended for this category of patients comprise breast tests done a specialized medical facility, MRI fro breasts and mammograms.

Guidelines for Cervical Cancer

Females who present an average predisposition for developing cervical cancer, the new guidelines suggest that those who are aged less than 21 years get a liquid based cytology or a Papanicolau tests in maximum three years after their first sexual intercourse. The woman should get Papanicolau tests done on a yearly basis until she scored three consecutive negative results. After this process, the scientists from M. D. Anderson’s Cancer Prevention Center suggest that the girl would undergo a once every two years screening if she does not present an enhanced predisposition of developing cervical cancer. The agents of risk comprise: immune system that does not operate accurately, the presence in the woman`s system of HIV (Human Immunodeficiency Virus), family history such as exposure before her birth to DES (diethylstilbestrol), the history of one`s cervical malignant tumors and advanced cervical dysplasia and continuously getting HPV (Human Papilloma Virus) positive results.

Starting with 30 years of age, the scientists recommend also testing for the Human
Papilloma Virus instead of the Papanicolau test and in the situation that both come up negative, a female could undergo tests once every three years unless she presents an enhanced predisposition to cervical cancer based in the mentioned agents or unless the recommended Human Papilloma Virus testing was not undergone.

Guidelines for Colorectal Cancer

The new investigation provided by the scientists from M. D. Anderson’s Cancer Prevention Center suggests that a colonoscopy should be done once every ten years and a virtual colonoscopy once every five years. The latter can be substituted by a FOBT (Fecal Occult Blood Test) done on a yearly basis in the case of both men and women who are 50 years or older and who present an average predisposition of developing colorectal cancer.

Taking into consideration both men and women who present an enhanced predisposition or a high risk of developing colorectal malignant tumors, the frequency and variety of medical tests depend on a series of agents such as: genetic history and diagnosis of Hereditary Nonpolyposis Colorectal Cancer and Familial Adenomatous Polyposis, ulcerative colitis, Crohn’s disease or any other inflammatory bowel disease, family and personal history of colorectal cancers or adenomatous polyps. Therapies recommended for this risk group comprise colonoscopies and flexible sigmoidoscopy.

Ernest Hawk is the vice-president of the Cancer Prevention and Population Sciences. As this medical doctor states due to the fact that the investigation was done both in labs and clinics within the M. D. Anderson’s Cancer Prevention Center and all over the Globe, the knowledge and comprehension regarding the means by which malignant tumors appear and develop are continuously increasing.

This constant increase in the acquired information is going to lead in a more transparent understanding from the patients` behalf of just how their physicians settle on a specific decision related to the screening exams and levels of risk. Furthermore, the cancer suffering people would be also able to comprehend better the way their illness functions and evolves and is prone to make them assess their own predisposition to developing cancer.

As doctor Bevers explains in the case of colorectal malignant tumors screening, patients have to present a proactive attitude about obtaining outcomes from their testing processes. Take for example the case in which polyps are uncovered during a colonoscopy. It is very important for the person in case to understand what type, size and number the polyp has since this discovery has a great deal to do with the predisposition category the patient belongs to.

The categories of cancer predisposition and linked frameworks were created by many departments coming from M. D. Anderson’s Cancer Prevention Center comprising: medical and surgical oncology, imaging, cancer prevention and so on and so forth. The framework related to the screening based on the predisposition of developing prostate, skin, liver, ovarian and endometrial malignant tumors is now underway. Furthermore, a new Internet tool for assessing one`s predisposition to cancer which in linked to the future guidelines is going to be released on the M. D. Anderson’s Cancer Prevention Center Internet site in the beginning of the year 2010.

Richard Barth Jr. is an associate professor in the surgery department of the DHMS (Dartmouth-Hitchcock Medical Center). His team of investigators comprised medical doctor Wendy Wells who is also a professor within the Dartmouth Medical School, in the pathology department. These two investigators also work in the Comprehensive Breast Care Program at Dartmouth-Hitchcock’s Norris Cotton Cancer Center. In the Dartmouth-Hitchcock Medical Center thirteen females took part in the research.

The group of researchers suggests the use of helpful radiotherapy in the cases of women who opt for the surgery that keeps the breasts intact in order to gain control over the borderline malignant tumor and over the phyllodes tumors.

The team`s recommendations were presented in the Annals of Surgical Oncology in the August edition.

The investigators observed a sample of 46 women who were treated with radiotherapy within 30 various medical clinics ranging over eighteen states. The group of scientists discovered that no woman presented new malign tumors in the states in which the doctors resected the tissue that tested malign negative and was nearby the cancer tumors.

Between approximately 500 females that are found suffering from these rare breast cancers on a Global basis per year and are treated only by undergoing surgery, the investigators state that the recurrence rate sums up 24% in the cases of women suffering from borderline malignant tumors and 20% in the cases of patients suffering from malignant tumors.

The research was financed by the Wellcome Trust and the Danish Cancer Society. It was released in the Nature Genetics and was provided by investigators from the University of Oxford and Copenhagen University Hospital.

Genetic mutations can affect various body cells in different moments of one`s life span. Some of the transformations affect the cells that develop sperm of female eggs and may trigger mutations that burden the child. Other mutations may take place in different body cells and develop in tumors, but these types are not genetic.

This recent research studies the association between specific, rare children inherited conditions and rare tumors that affect the testicles in the case of older patients. The sperm of eggs that are the product of changed germ cells appear to be the causes of these rare testicular tumors.

Even though the first transformations seldom appear in the germ cells, they trigger the mutant tissues to increase. In the cellular division process, a cell that has a transformation in its DNA transfers this bias to all its replicas and taking into consideration the germ cells which produce sperm, these mutations are transferred to all the spermatozoids. Thus, this propensity in the sperm mutation increases in the case of older males, at the same time increasing their chances to conceive children with health conditions.

Leading the research was professor Andrew Wilkie from the University of Oxford. He stated that his team thought that older men developed mutated bundle of cells as they grew older. These bundles commonly produce no harm and may appear as moles located on the skin`s surface. However, if the mutated bundle of cells is found in the testicles it may trigger the conception of offspring who present various poor health conditions. The team of scientists entitled these bundles “selfish” due to the fact that they do not affect their host, in this case the older fathers, but bring upon a serious burden to the children conceived by these fathers.

This study aids doctors in discovering the triggering causes of some bad health conditions that interact with the offspring`s good evolution. Some of the serious health conditions that may appear due to the cellular mutations sum up Apert, Costello and Noonan syndromes, achondroplasia and even the death of the fetus inside the female`s uterus or at the moment of birth. In additions, the research also associated these diseases to a framework which controls the division of the cells. The study is more valuable as it can give the medical staff the chance to present to the parents the causes which triggered the poor health condition of their children and also make them aware of the diseases incidence risk. However, in the majority of the cases, there is a slight chance that future child conceptions would be affected by the genetic mutations.

The outcomes of the research may also shed some light in one of the greatest questions related to genetics. What is the mechanism for the genetic material to be a major element in the appearance and development of similar illnesses? Similar illnesses are triggered by a number of genes that interact with each other. However, even if doctors analyzed the relationship between the genome and these genes, a small number of them was revealed. Some of the health conditions, comprising breast malign tumors, autism and schizophrenia, appear to have an increased development risk in children who were conceived by older fathers. However, the reasons for these are not still known. Professor Andrew Wilkie states that some of these conditions may be triggered by similar but less aggressive gene transformations.

As the leading investigator explains, the research may have studied only 10% or less of the less aggressive gene transformations which are presented in the human genome. However, as he continues, the gene mutations are either too rare or too weak to be detected by nowadays technology. Nonetheless, their accurate number has a summing up effect and triggers health conditions.

The team of investigators state that additional investigations need to be done in order to discover other genes which may be affected by the mutation process. Nonetheless, the technology for sequencing the DNA has moved at a higher level and is able now to gather a wider sequence in just a day compared to what was in the past when the same amount of sequence was obtained over the time span of almost an entire year. This obsolete technology was available only ten years ago. The scientists hope that these progresses done in the DNA sequencing process would evolve with the passing of the years and enable researchers to find out the actual risk of children being affected by the genetic mutations of the germ cell from their fathers` bodies.

This framework was created during last year, in a joint effort of twenty researchers each having different specializations. The members of the investigation team studied various published materials regarding the brain metastasis and managed to get to a compromise in conducting various therapies against this disease. Medical doctor Steven Kalkanis who is one of the directors of the Hermelin Brain Tumor Center within the Detroit`s Henry Ford Hospital, was the leading member of the research team.

The research is based only on the existing and tested evidence and was supported both by the Congress of Neurological Surgeons and American Association of Neurological Surgeons and by the Joint Tumor Section accompanied by specialists in a variety of fields such as: radiation, oncology and neurosurgery.

Neurosurgeon Steven Kalkanis stated that in the past ten years, a multitude of therapies against the brain metastases was discovered and developed, treatments such as: the surgical cut off the malign tissues, stereotactic radio-operation, partial and/or whole brain radiation treatments, chemo and numerous combinations of these. Due to this increased number of counteracting therapies, neurosurgeons used a variety of combinations in order to aid their patients, but this had as a negative effect the fact that until this specific study, no one really knew which of these represents the most efficient treatment of combination of treatments. Therefore, doctor Kalkanis` team sought to find which is the most effective and efficient treatment of them all.

It seems that in the year 2008, as leading investigator states, 1.4 million people suffered from cancer. Out of them, ranging between 30% and 40% of the individuals will evolve in suffering from brain metastasis. This is primarily triggered by the fact that lung or breast cancers form malign cells which travel in the blood flow to the brain affecting it as well.

Nonetheless, approximately 17,000 people develop new cases of brain malign tumors that will develop and metastasize in the brain.

In the situations in which there was not enough information to generate a framework for treatment or even a pathway to be followed in order to reach a proper therapy guideline, the research presents all the significant and important clinical tests that are still underway as well as the important investigations that need to be undergone in the future in order to gain knowledge about the brain metastases. This will assure future information and support in the battle against this disease.

The research team developed a new brain metastases treatment framework which comprises a variety of treatment possibilities for counteracting the brain metastasis, the current knowledge which is utilized in the pattern of decision-making and this practice`s limits regarding the disease, some demographic agents which can bias the clinical outcomes, the various specific practices of treatment and the influence of the testimonials of the specialized doctors for the clinical evidence released on the practice part of the treatment.

Leading the research was professor doctor Johannes Wolff from the Children’s Cancer Hospital within the M. D. Anderson Cancer Center. He stated that the new protocol comprises three chemotherapy factors and irradiation and forecasts a rate of survival of 93% for the first year, 83% in the next five and 78% in eight years.

As Doctor Wolff explains the research began a decade ago and was entitled SIOP 2000. Since its early beginnings, the project expanded and now comprises over 100 institutions located in over 20 countries. Due to this amalgam of cultures and institutions, the researchers were able to examine huge amounts of data and are now able to say which ill persons are going to improve their health and which ones have small chances of recovery. Moreover, the team of investigators managed to develop a standard protocol for the children with low expectancy of survival.

The malignant tumors entitled choroid plexus affect the brain. Their origin is in the choroid plexus epithelium which represents an important element for the human body since it is the agent that creates the cerebrospinal fluid. In the majority of the cases, the malignant tumors block the free flow of the cerebrospinal fluid, an action which produces pressure in the brain and may lead to an enlarged skull. This condition is a very rare type of cancer which affects almost 1,500 children per year all over the Globe. The majority of the cases are encountered in infants.

The international team of investigators desire to find new methods of therapy to counteract the choroid plexus, but this is a hard job due to the rarity of this condition. There are not any standard therapeutic mechanisms to combat these malign tumors. However, the scientists did not give up and managed to create a brand new statistical model in order for the institutions to acquire high quality and effective data provided by the research.

Surprisingly, Wolff`s international team found a rather shocking thing which was in complete contradiction with the traditional practices in the cases of choroid plexus suffering patients. If it was customary in the past to treat this illness by surgery and total resection of the malignant tumor, the SIOP 2000 investigation showed that children who were treated with aggressive chemotherapy showed almost the same results as the ones that underwent surgery. This finding meant that the stressful surgery protocol was not a major element in treating the choroid plexus and diminished the need to undergo operation.

As Doctor Wolff states that they have a hypothesis rising from the cases in which the medical doctors extended the time span for chemotherapy in children. If it proves to be correct, the team`s hypothesis may provide a reason for prolonging the chemo treatment for a longer period of time.

Moreover, the leading author of the study says that the next phase of the research is to undergo another investigation in a four-armed chemo treatment. By doing this, the scientists would examine the opportunity of bringing another chemo so as to enhance the survival time span for children. The chemotherapy protocols used in the SIOP 2000 research comprised irradiation, carboplatinum, etoposide and cyclophosamide.